The neuropathology and cerebrovascular mechanisms of dementia

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 1, 2016, Pages 172-186

  Raz, Limor ^a   Knoefel, Janice ^a   Bhaskar, Kiran ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; cerebrovascular; cognitive impairment; hypoxia; review

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PRESENILIN 1; SIRTUIN 1; TAR DNA BINDING PROTEIN;

ALZHEIMER DISEASE; BIOENERGY; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; HYPERTENSION; HYPOXIA; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TAUOPATHY; CEREBROVASCULAR DISORDERS; COMPLICATION; LEWY BODY; NEURODEGENERATIVE DISEASES; NEUROGENIC INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE;

BLOOD-BRAIN BARRIER; CEREBROVASCULAR DISORDERS; DEMENTIA; HUMANS; LEWY BODIES; NEURODEGENERATIVE DISEASES; NEUROGENIC INFLAMMATION; PREVALENCE; RISK FACTORS;

EID: 84949908018     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.164     Document Type: Review

References (148)

1. Hershey LA, Modic MT, Jaffe DF and Greenough PG. Natural history of the vascular dementias: a prospective study of seven cases. Can J Neurol Sci 1986; 13: 559-565
2. Loeb C. The history of vascular dementia. J Hist Neurosci 1995; 4: 121-126
3. Hachinski VC, Lassen NA and Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2: 207-210
4. Pantoni L and Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997; 28: 652-659
5. Suri S, Topiwala A, Mackay CE, Ebmeier KP and Filippini N. Using structural and diffusion magnetic resonance imaging to differentiate the dementias. Curr Neurol Neurosci Rep 2014; 14: 475
6. Villeneuve S, Reed BR, Madison CM, Wirth M, Marchant NL, Kriger S, et al. Vascular risk and Ab interact to reduce cortical thickness in AD vulnerable brain regions. Neurology 2014; 83: 40-47
7. Honjo K, Black SE and Verhoeff NP. Alzheimer's disease, cerebrovascular disease, and the b-amyloid cascade. Can J Neurol Sci 2012; 39: 712-728
8. Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, et al. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 2005; 57: 98-103
9. Schreiber S, Bueche CZ, Garz C and Braun H. Blood brain barrier breakdown as the starting point of cerebral small vessel disease New insights from a rat model. Exp Transl Stroke Med 2013; 5: 4
10. Farkas E, De Jong GI, de Vos RA, Jansen Steur EN and Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 2000; 100: 395-402
11. Yang Y and Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42: 3323-3328
12. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/ american Stroke Association. Stroke 2011; 42: 2672-2713
13. Stefani A, Sancesario G, Pierantozzi M, Leone G, Galati S, Hainsworth AH, et al. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. J Neurol Sci 2009; 283: 109-115
14. De Reuck J, Deramecourt V, Cordonnier C, Leys D, Pasquier F and Maurage CA. Prevalence of cerebrovascular lesions in patients with Lewy body dementia: a neuropathological study. Clin Neurol Neurosurg 2013; 115: 1094-1097
15. Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J, et al. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimerrelated co-pathologies. J Neural Transm, e-pub ahead of print 4 January 2015
16. Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H, et al. Multiple or mixed cerebral microbleeds and dementia in patients with vascular risk factors. Neurology 2014; 83: 646-653
17. Valenti R, Pantoni L and Markus HS. Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review. BMC Med 2014; 12: 160
18. Jellinger KA and Attems J. Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol 2012; 31: 87-98
19. Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, et al. Ecology of the aging human brain. Arch Neurol 2011; 68: 1049-1056
20. SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT and Tyas SL. Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. J Neuropathol Exp Neurol 2011; 70: 832-840
21. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA and Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817
22. Wortmann M. Dementia: a global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 2012; 4: 40
23. Hurd MD, Martorell P, Delavande A, Mullen KJ and Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 368: 1326-1334
24. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al. Alzheimer's disease is not ''brain aging'': neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 2011; 121: 571-587
25. Shim YS, Roe CM, Buckles VD and Morris JC. Clinicopathologic study of Alzheimer's disease: Alzheimer mimics. J Alzheimers Dis 2013; 35: 799-811
26. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13
27. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM and Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68: 19-31
28. Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80: 844-866
29. Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
30. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381
31. Huang Y and Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-1222
32. Serrano-Pozo A, Frosch MP, Masliah E and Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189
33. Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, et al. Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. PLoS One 2012; 7: e36893
34. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, et al. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res 2003; 25: 642-651
35. Charidimou A, Gang Q and Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83: 124-137
36. Dietrich HH, Xiang C, Han BH, Zipfel GJ and Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 2010; 5: 15
37. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, et al. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 2005; 25: 1769-1777
38. Thomason LA, Stefanovic B and McLaurin J. Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models. Eur J Neurosci 2013; 37: 1994-2004
39. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923
40. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014; 83: 253-260
41. Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-e2 and APOE-e4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol 2013; 72: 708-715
42. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002; 16: 203-212
43. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28
44. Alzheimer's A. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014; 10: e47-e92
45. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R and Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840
46. De Reuck J, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D, et al. Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. J Neurol Sci 2014; 346: 85-89
47. Miners S, Moulding H, de Silva R and Love S. Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies. Brain Pathol 2014; 24: 334-343
48. Mackenzie IR. Activated microglia in dementia with Lewy bodies. Neurology 2000; 55: 132-134
49. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 2011; 26: 171-179
50. Nielsen HM, Palmqvist S, Minthon L, Londos E and Wennstrom M. Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia. Curr Alzheimer Res 2012; 9: 257-266
51. Ghebremedhin E, Rosenberger A, Rub U, Vuksic M, Berhe T, Bickeboller H, et al. Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases. J Neuropathol Exp Neurol 2010; 69: 442-448
52. Nedelska Z, Ferman TJ, Boeve BF, Przybelski SA, Lesnick TG, Murray ME, et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015; 36: 452-461
53. Onyike CU and Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry 2013; 25: 130-137
54. Rabinovici GD and Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010; 24: 375-398
55. Pan XD and Chen XC. Clinic, neuropathology and molecular genetics of frontotemporal dementia: a minireview. Transl Neurodegener 2013; 2: 8
56. Neary D, Snowden J and Mann D. Frontotemporal dementia. Lancet Neurol 2005; 4: 771-780
57. Perri R, Monaco M, Fadda L, Caltagirone C and Carlesimo GA. Neuropsychological correlates of behavioral symptoms in Alzheimer's disease, frontal variant of frontotemporal, subcortical vascular, and lewy body dementias: a comparative study. J Alzheimers Dis 2014; 39: 669-677
58. Warren JD, Rohrer JD and Rossor MN. Clinical review. Frontotemporal dementia. BMJ 2013; 347: f4827
59. Lee VM, Goedert M and Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-1159
60. Hu WT and Grossman M. TDP-43 and frontotemporal dementia. Curr Neurol Neurosci Rep 2009; 9: 353-358
61. Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 2007; 113: 521-533
62. Mariani C, Defendi S, Mailland E and Pomati S. Frontotemporal dementia. Neurol Sci 2006; 27: S35-S36
63. Kalkonde YV, Jawaid A, Qureshi SU, Shirani P, Wheaton M, Pinto-Patarroyo GP, et al. Medical and environmental risk factors associated with frontotemporal dementia: a case-control study in a veteran population. Alzheimers Dement 2012; 8: 204-210
64. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136: 2697-2706
65. Jawaid A, Rademakers R, Kass JS, Kalkonde Y and Schulz PE. Traumatic brain injury may increase the risk for frontotemporal dementia through reduced progranulin. Neurodegener Dis 2009; 6: 219-220
66. Moorhouse P and Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 2008; 7: 246-255
67. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409-427
68. Pendlebury ST and Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8: 1006-1018
69. Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST, et al. Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol 2013; 73: 584-593
70. Chui HC. Subcortical ischemic vascular dementia. Neurol Clin 2007; 25: 717-740
71. Roh JH and Lee JH. Recent updates on subcortical ischemic vascular dementia. J Stroke 2014; 16: 18-26
72. Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J, et al. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 2011; 42: 2158-2163
73. Rosenberg GA, Bjerke M and Wallin A. Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. Stroke 2014; 45: 1531-1538
74. Paquet C, Jouvent E, Mine M, Vital A, Hugon J, Chabriat H, et al. A cortical form of CADASIL with cerebral Abeta amyloidosis. Acta Neuropathol 2010; 120: 813-820
75. Langa KM, Foster NL and Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004; 292: 2901-2908
76. Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al. Vascular dementia in a populationbased autopsy study. Arch Neurol 2003; 60: 569-575
77. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169-175
78. Schneider JA, Arvanitakis Z, Leurgans SE and Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66: 200-208
79. Haan MN, Shemanski L, Jagust WJ, Manolio TA and Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999; 282: 40-46
80. Bugiani O. A beta-related cerebral amyloid angiopathy. Neurol Sci 2004; 25: S1-S2
81. Gold G, Giannakopoulos P, Herrmann FR, Bouras C and Kovari E. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 2007; 130: 2830-2836
82. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S and Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551
83. Gupta A, Preis SR, Beiser A, Devine S, Hankee L, Seshadri S, et al. Mid-life cardiovascular risk impacts memory function: the Framingham Offspring Study. Alzheimer Dis Assoc Disord 2014; 29: 117-123
84. Pires PW, Dams Ramos CM, Matin N and Dorrance AM. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol 2013; 304: H1598-H1614
85. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012; 59: 780-786
86. Bueche CZ, Hawkes C, Garz C, Vielhaber S, Attems J, Knight RT, et al. Hypertension drives parenchymal betaamyloid accumulation in the brain parenchyma. Ann Clin Transl Neurol 2014; 1: 124-129
87. Schreiber S, Drukarch B, Garz C, Niklass S, Stanaszek L, Kropf S, et al. Interplay between age, cerebral small vessel disease, parenchymal amyloid-beta, and tau pathology: longitudinal studies in hypertensive stroke-prone rats. J Alzheimers Dis 2014; 42: S205-S215
88. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352
89. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, et al. Hypertension induces brain betaamyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 2012; 60: 188-197
90. Cifuentes D, Poittevin M, Dere E, Broqueres-You D, Bonnin P, Benessiano J, et al. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension 2015; 65: 218-224
91. Scioli MG, Bielli A, Arcuri G, Ferlosio A and Orlandi A. Ageing and microvasculature. Vasc Cell 2014; 6: 19
92. Austin SA, Santhanam AV, Hinton DJ, Choi DS and Katusic ZS. Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. J Neurochem 2013; 127: 691-700
93. Butterfield DA, Di Domenico F, Swomley AM, Head E and Perluigi M. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J 2014; 463: 177-189
94. Hattori Y, Okamoto Y, Maki T, Yamamoto Y, Oishi N, Yamahara K, et al. Silent information regulator 2 homolog 1 counters cerebral hypoperfusion injury by deacetylating endothelial nitric oxide synthase. Stroke 2014; 45: 3403-3411
95. Kaminsky YG, Tikhonova LA and Kosenko EA. Critical analysis of Alzheimer's amyloid-beta toxicity to mitochondria. Front Biosci (Landmark Ed) 2015; 20: 173-197
96. Ritz MF, Grond-Ginsbach C, Engelter S and Lyrer P. Gene expression suggests spontaneously hypertensive rats may have altered metabolism and reduced hypoxic tolerance. Curr Neurovasc Res 2012; 9: 10-19
97. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG and O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000; 15: 911-916
98. Golimstok A, Campora N, Rojas JI, Fernandez MC, Elizondo C, Soriano E, et al. Cardiovascular risk factors and frontotemporal dementia: a case-control study. Transl Neurodegener 2014; 3: 13
99. Weaver J, Jalal FY, Yang Y, Thompson J, Rosenberg GA and Liu KJ. Tissue oxygen is reduced in white matter of spontaneously hypertensive-stroke prone rats: a longitudinal study with electron paramagnetic resonance. J Cereb Blood Flow Metab 2014; 34: 890-896
100. Jalal FY, Yang Y, Thompson J, Lopez AC and Rosenberg GA. Myelin loss associated with neuroinflammation in hypertensive rats. Stroke 2012; 43: 1115-1122
101. Takeda S, Sato N and Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/ non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci 2014; 6: 171
102. Nagga K, Wattmo C, Zhang Y, Wahlund LO and Palmqvist S. Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. Alzheimers Res Ther 2014; 6: 41
103. Serrano-Pozo A, Muzikansky A, Gomez-Isla T, Growdon JH, Betensky RA, Frosch MP, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 2013; 72: 462-471
104. Bhaskar K, Maphis N, Xu G, Varvel NH, Kokiko-Cochran ON, Weick JP, et al. Microglial derived tumor necrosis factor-alpha drives Alzheimer's diseaserelated neuronal cell cycle events. Neurobiol Dis 2014; 62: 273-285
105. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J and Campos-Pena V. Inflammatory process in Alzheimer's Disease. Front Integr Neurosci 2013; 7: 59
106. Hawkes CA and McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2009; 106: 1261-1266
107. Michaud JP, Bellavance MA, Prefontaine P and Rivest S. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep 2013; 5: 646-653
108. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P and Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004; 3: 169-176
109. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14: 388-405
110. Zotova E, Nicoll JA, Kalaria R, Holmes C and Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2010; 2: 1
111. Davies AL, Desai RA, Bloomfield PS, McIntosh PR, Chapple KJ, Linington C, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol 2013; 74: 815-825
112. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732
113. Jalal FY, Yang Y, Thompson JF, Roitbak T and Rosenberg GA. Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/ SP. J Cereb Blood Flow Metab 2015; 35: 1145-1153
114. Dominguez de Villota ED, Ruiz Carmona MT, Rubio JJ and de Andres S. Equality of the in vivo and in vitro oxygen-binding capacity of haemoglobin in patients with severe respiratory disease. Br J Anaesth 1981; 53: 1325-1328
115. Kaminsky YG, Reddy VP, Ashraf GM, Ahmad A, Benberin VV, Kosenko EA, et al. Age-related defects in erythrocyte 2,3-diphosphoglycerate metabolism in dementia. Aging Dis 2013; 4: 244-255
116. Ferrer I, Gomez A, Carmona M, Huesa G, Porta S, Riera-Codina M, et al. Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies. J Alzheimers Dis 2011; 23: 537-550
117. Chuang JY, Lee CW, Shih YH, Yang T, Yu L and Kuo YM. Interactions between amyloid-beta and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. PLoS One 2012; 7: e33120
118. Lin AJ, Liu G, Castello NA, Yeh JJ, Rahimian R, Lee G, et al. Optical imaging in an Alzheimer's mouse model reveals amyloid-dependent vascular impairment. Neurophotonics 2014; 1: 011005
119. Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord 2013; 19: 47-52
120. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 2013; 4: 1562
121. Bellucci A, Bugiani O, Ghetti B and Spillantini MG. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis 2011; 8: 221-229
122. Kaiser D, Weise G, Moller K, Scheibe J, Posel C, Baasch S, et al. Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease. Acta Neuropathol Commun 2014; 2: 169
123. Goldsworthy MR and Vallence AM. The role of betaamyloid in alzheimer's disease-related neurodegeneration. J Neurosci 2013; 33: 12910-12911
124. Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One 2013; 8: e59586
125. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128
126. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216
127. Jack CR Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014; 13: 997-1005
128. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014; 71: 1379-1385
129. Cortes-Canteli M, Mattei L, Richards AT, Norris EH and Strickland S. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging2014
130. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. Nature 1998; 395: 755-756
131. Frost B, Gotz J and Feany MB. Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol 2015; 25: 46-53
132. Foster V, Oakley AE, Slade JY, Hall R, Polvikoski TM, Burke M, et al. Pyramidal neurons of the prefrontal cortex in post-stroke, vascular and other ageing-related dementias. Brain 2014; 137: 2509-2521
133. Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, et al. A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun 2010; 1: 110
134. Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci 2013; 33: 5352-5361
135. Muoio V, Persson PB and Sendeski MM. The neurovascular unit-concept review. Acta Physiol (Oxf) 2014; 210: 790-798
136. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32: 1139-1151
137. Yang Y, Thompson JF, Taheri S, Salayandia VM, McAvoy TA, Hill JW, et al. Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J Cereb Blood Flow Metab 2013; 33: 1104-1114
138. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68: 1411-1416
139. Sagare AP, Bell RD and Zlokovic BV. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a011452
140. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M and Zlokovic BV. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 2013; 23: 303-310
141. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 2013; 4: 2932
142. De Reuck J, Deramecourt V, Cordonnier C, Auger F, Durieux N, Bordet R, et al. Detection of microbleeds in post-mortem brains of patients with frontotemporal lobar degeneration: a 7.0-Tesla magnetic resonance imaging study with neuropathological correlates. Eur J Neurol 2012; 19: 1355-1360
143. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I and Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand 1990; 81: 318-322
144. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998; 50: 966-971
145. Rosenberg GA, Sullivan N and Esiri MM. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001; 32: 1162-1168
146. Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 2014; 11: 710-717
147. Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014; 82: 1760-1767
148. Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM, et al. Recommendations of the Alzheimer's disease-related dementias conference. Neurology 2014; 83: 851-860.